Immunology companies study and manipulate the immune system to develop therapies, diagnostics and research tools. The field plays a central role in areas such as cancer, infectious disease, autoimmune disorders and vaccine development.
This category includes companies working on:
Browse 182 UK immunology companies below.
AI-powered immune profiling platform for precision medicine
IMU Biosciences is a biotechnology company coupling high-resolution, systems-level immune profiling with proprietary AI analytics to build a detailed atlas of the human immune system across health and disease. Its platform can identify and analyse over 2,000 immune cell subsets from blood samples, generating…
First-in-class small molecule therapeutics targeting DNA uracilation in cancer
CV6 Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule drugs for cancer and inflammatory diseases. Its lead asset CV6-168 is a specific inhibitor of the enzyme dUTPase, inducing uracil misincorporation into cancer cell DNA, triggering DNA damage and immune activation.…
Research antibodies, proteins and ELISA kits for life science laboratories
Antibodies.com is a supplier of research reagents for life science laboratories, offering a catalogue of more than 100,000 products. Its range includes primary and secondary antibodies, recombinant proteins, ELISA kits and other assay kits used in applications such as western blotting, immunohistochemistry, flow…
T cell-based tuberculosis diagnostics and clinical laboratory testing services
Oxford Immunotec is an Abingdon-based diagnostics company developing, manufacturing, and supplying T cell-based diagnostic tests for infectious and immunological diseases. Its platform measures specific T cell immune responses to inform clinical diagnosis, with the T-SPOT.TB test for tuberculosis detection cleared by…
TCR bispecific immunotherapies for cancer and infectious disease
Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025. Three Phase 3 trials are enrolling across melanoma indications, with topline data…
T cell immune monitoring products and immunology contract research
ImmunoServ is a Welsh contract research and diagnostics company specialising in T cell immunology and cancer immunotherapy. The company develops and supplies standardised T cell testing kits that measure antigen-specific cellular immune responses from blood samples, with applications in infectious disease…
Human skin explant CRO for immunotoxicity and drug safety testing
Alcyomics is a contract research organisation providing non-animal, human-based in vitro safety and efficacy testing services to pharmaceutical, biotechnology, and cosmetics clients. Its core assay technology uses non-artificial human skin explants to predict adverse immune reactions, including cytokine storm and skin…
AstraZeneca's rare disease arm targeting the complement cascade
Alexion, AstraZeneca Rare Disease is the rare disease group within AstraZeneca, formed following the 2021 acquisition of Alexion Pharmaceuticals. With nearly 30 years of rare disease heritage, the division focuses on novel molecules targeting the complement cascade across haematology, nephrology, neurology, metabolic…
Antibody therapies depleting pathogenic T cells for autoimmune disease cure
Re-Aim Therapeutics is a biotechnology company developing antibody-based therapies designed to achieve functional cures for T cell-mediated autoimmune diseases. The company's approach selectively depletes pathogenic T cell subsets that drive chronic inflammation, using precise targeting of disease-relevant membrane…
Antibody therapy to deplete amyloid deposits in ATTR cardiomyopathy
Immutrin is a biotechnology company developing an engineered antibody therapeutic designed to actively remove amyloid deposits from tissues in patients with amyloidosis. Its lead asset targets ATTR cardiomyopathy, a progressive and often fatal cardiac disease caused by transthyretin amyloid accumulation, for which no…
In vitro immunology CRO for pre-clinical drug development
Immundnz is a contract research organisation specialising in in vitro immunology services for pharmaceutical and biotechnology clients. The company designs and applies customised and standard immunological assays to assess immune safety, efficacy, and response to candidate therapeutics during pre-clinical development.…
Synthetic plant metabolites for osteoarthritis and age-related disease
AKL Therapeutics is a privately held UK pharmaceutical company developing APPA, a patented oral investigational medicine combining two synthetic plant metabolites that act synergistically to target multiple signalling pathways in osteoarthritis. Animal studies have demonstrated pain reduction and delayed cartilage…
Multiplex nanophotonic blood testing platform for point-of-care diagnostics
Attomarker is a developer of point-of-care multiplex diagnostic devices using proprietary gold nanoparticle nanophotonic technology. Its platform measures up to 20 biomarkers simultaneously from a single finger-prick blood sample, delivering quantitative results within minutes. Tests are UKCA-marked and in clinical…
Clinical-stage peptide therapeutics for autoimmune and infectious disease
ImmuPharma is a clinical-stage biopharmaceutical company developing peptide-based therapeutics and precision diagnostics for autoimmune disease, infectious disease and metabolic disorders. Its lead candidate, a first-in-class immunormalizer for lupus, has completed a Phase III pivotal trial, aiming to restore normal…
Oncolytic virus platform for tumour-targeted cancer immunotherapy
Accession Therapeutics is a clinical-stage biotechnology company developing tumour-targeted immunotherapies based on its proprietary oncolytic virus platform. Designed for systemic delivery, the platform selectively replicates within cancer cells to generate therapeutic payloads locally at the tumour site. The…
Preclinical immunology CRO for drug discovery programmes
Nexus BioQuest is a contract research organisation specialising in preclinical immunology services for the biotechnology and pharmaceutical industries. The company offers bespoke assay development and in vitro screening across immuno-oncology, autoimmunity, inflammation, and neuroinflammation, including cytokine…
Clinical-stage developer of oncolytic immunotherapies for cancer treatment
Replimune is the UK research and development site of Replimune Group, a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its platform uses genetically engineered herpes simplex viruses to selectively replicate within and destroy tumour cells, releasing tumour antigens and…
Preclinical DMPK, bioanalysis and toxicology CRO
Pharmidex is a UK contract research organisation providing preclinical drug discovery and development services across DMPK, bioanalysis, toxicology, histology and in vitro ADME. Operating under GLP and GCP accreditation from its Hatfield facility, the company supports programmes in oncology, CNS, respiratory and…
Gene therapy immune regulators for infection, cancer and autoimmunity
Virothera develops gene therapies intended to regulate immune responses in persistent diseases. Its approach draws on human versions of immune-modifying proteins that viruses have evolved to influence immune cells. The company aims to use these proteins to create targeted treatments with potential advantages over some…
Plasma fractionation and manufacture of plasma-derived therapies
Kedrion Biopharma is a biopharmaceutical manufacturer specialising in the fractionation of human blood plasma to produce albumin solutions, immunoglobulins and coagulation factors for the treatment of rare and life-threatening conditions including immunodeficiencies and bleeding disorders. Operating from a 130,000…